The evolving role for re-irradiation in the management of recurrent grade 4 glioma.
By: Steven P Howard, Andra Krauze, Mike D Chan, Christina Tsien, Wolfgang A Tomé

Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, K4/350 Clinical Science Center, 600 Highland Avenue, Madison, WI, 53792, USA. howard@humonc.wisc.edu.
2016-11-10; doi: 10.1007/s11060-017-2392-1
Abstract

Although significant gains have been realized in the management of grade 4 glioma, the majority of these patients will ultimately suffer local recurrence within the prior field of treatment. Clearly, novel local treatment strategies are required to improve patient outcomes. Concerns of toxicity have limited enthusiasm for the utilization of re-irradiation as a treatment option. However, using modern imaging technology and precision radiotherapy delivery techniques re-irradiation has proven a feasible option achieving both a palliative benefit and prolongation of survival with low toxicity rates. The evolution of re-irradiation as a treatment modality for recurrent grade 4 glioma is reviewed. In addition, potential targeted radiosensitizers to be used in conjunction with re-irradiation are also discussed.





PMID:28386661






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements